The D2 receptor occupancy profile of loxapine determined using PET

Neuropsychopharmacology

Volumn 15, Issue 6, 1996, Pages 562-566

  Kapur, Shitij ^a   Zipursky, Robert B ^b   Jones, Corey ^b   Remington, Gary J ^b   Wilson, Alan A ^b   DaSilva, Jean ^b   Houle, Sylvain ^b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b NONE

Author keywords

Antipsychotics; Dopamine receptors; Loxapine; Positron emissin tomography; Schizophrenia; 11C raclopride

Indexed keywords

DOPAMINE RECEPTOR; LOXAPINE; RACLOPRIDE; CARBON; DIAGNOSTIC AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; SALICYLAMIDE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CORPUS STRIATUM; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CROSS-SECTIONAL STUDY; DRUG EFFECT; METABOLISM; METHODOLOGY; PSYCHOSIS; SCINTISCANNING;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; CARBON RADIOISOTOPES; CORPUS STRIATUM; CROSS-SECTIONAL STUDIES; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; LOXAPINE; MALE; PSYCHOTIC DISORDERS; RACLOPRIDE; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030300171     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(96)00100-5     Document Type: Article

References (15)

1. Antonini A, Leenders KL, Reist H, Thomann R, Beer HF, Locher J (1993): Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride. Arch Neurol 50:474-80
2. Bezchlibnyk-Butler KZ, Jeffries JJ (1991): Clinical Handbook of Psychotrophic Drugs. Toronto, Hans Huber Publishers
3. Bishop MP, Simpson GM, Dunnett CW, Kiltie H (1977): Efficacy of loxapine in the treatment of paranoid schizophrenia. Psychopharmacology 51:107-115
4. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992): Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
5. Fruensgaard K, Korsgaard S, Jorgensen H, Jensen K (1977): Loxapine versus haloperidol parenterally in acute psychosis with agitation. A double-blind study. Acta Psychiatr Scand 56:256-264
6. 11C]-raclopride binding using a bolus plus infusion protocol. In Myers R, Cunningham B, Bailey D, Jones T (eds), Quantification of Brain Function Using PET. San Diego, CA Academic Press, pp 262-265
7. Janicak PG, Javaid JI, Sharma RP, Leach A, Dowd S, Davis JM (1995): A double-blind randomized study of three haloperidol plasma levels for acute psychosis. In New Research Program and Abstracts 148th Annual meeting of the APA, Washington, DC, APA Press Inc.
8. Kapur S, Remington G (1996): Serotonin-Dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466-476
9. Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, Zupursky R (1996): High levels of dopamine D2 receptor occupancy with low dose haloperidol treatment: A PET study. Am J Psychiatry, 153:948-950
10. Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S (1995): The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A PET study. Life Sci 57:PL103-PL107
11. McEvoy JP, Hogarty GE, Steingard S (1991): Optimal dose of neuroleptic in acute schizophrenia: A controlled study of neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 48:739-745
12. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G (1993): Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects - a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235.
13. Nyberg S, Farde L, Halldin C, Dahl ML, Bertilsson L (1995): D2 dopamine receptor occupancy during low-dose treatment with haloperiodol decanoate. Am J Psychiatry 152:173-178
14. Singh AN, Barlas C, Singh S, Franks P, Mishra RK (1996): A neurochemical basis for the antipsychotic activity of loxapine: Interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes. J Psychiatry Neurosci 21:1-7
15. Stone CK, Garver DL, Griffith J, Hirschowitz J, Bennett J (1995): Further evidence of a dose-response threshold for haloperidol in psychosis. Am J Psychiatry 152:1210-1212